Zunhao Zhang, Bo Tian, Hui Xu, He Huang, Xianwei Liang, Changwen Bo, Yunfei Bian, Ming Wei, Zhitao Zhao
{"title":"研究射波刀系统治疗原发性胰腺癌胃肠道转移的有效性和安全性。","authors":"Zunhao Zhang, Bo Tian, Hui Xu, He Huang, Xianwei Liang, Changwen Bo, Yunfei Bian, Ming Wei, Zhitao Zhao","doi":"10.2147/CMAR.S526924","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).</p><p><strong>Methods: </strong>A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.</p><p><strong>Results: </strong>Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).</p><p><strong>Conclusion: </strong>CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.</p>","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1589-1598"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338085/pdf/","citationCount":"0","resultStr":"{\"title\":\"Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.\",\"authors\":\"Zunhao Zhang, Bo Tian, Hui Xu, He Huang, Xianwei Liang, Changwen Bo, Yunfei Bian, Ming Wei, Zhitao Zhao\",\"doi\":\"10.2147/CMAR.S526924\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).</p><p><strong>Methods: </strong>A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.</p><p><strong>Results: </strong>Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).</p><p><strong>Conclusion: </strong>CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.</p>\",\"PeriodicalId\":9479,\"journal\":{\"name\":\"Cancer Management and Research\",\"volume\":\"17 \",\"pages\":\"1589-1598\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338085/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Management and Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/CMAR.S526924\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S526924","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract.
Objective: This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).
Methods: A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.
Results: Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1-25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38±1.37 at baseline to 2.01±0.35 post-treatment (p<0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).
Conclusion: CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.
期刊介绍：
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include:
◦Epidemiology, detection and screening
◦Cellular research and biomarkers
◦Identification of biotargets and agents with novel mechanisms of action
◦Optimal clinical use of existing anticancer agents, including combination therapies
◦Radiation and surgery
◦Palliative care
◦Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
